二甲双胍对侵袭性乳腺癌非糖尿病患者肿瘤细胞增殖指标的影响参考伊朗癌症研究所

S. Sadighi, M. Saberian, B. Behrouzi, M. Najafi, I. Jahanzad, R. Omranipour
{"title":"二甲双胍对侵袭性乳腺癌非糖尿病患者肿瘤细胞增殖指标的影响参考伊朗癌症研究所","authors":"S. Sadighi, M. Saberian, B. Behrouzi, M. Najafi, I. Jahanzad, R. Omranipour","doi":"10.18502/BCCR.V11I4.5725","DOIUrl":null,"url":null,"abstract":"Background: Because of the decreasing effect of metformin on insulin resistance, it has been suggested as an anti-obesity and anti-cancer drug. So, we aimed to study the effect of metformin therapy on tumor cell proliferation in non-diabetic breast cancer patients. Methods: We conducted a prospective clinical trial and studied the effect of metformin therapy on the level of Ki67 as a measure of tumor cell proliferation. Our primary endpoint was to evaluate the changes in Ki67. The intervention group consisted of 25 non-diabetic breast cancer patients with no indication for neoadjuvant chemotherapy. They were followed up from the time of biopsy to operation. Metformin (1500 mg/day) was prescribed in the intervention group from the date of diagnosis until the surgery (2.8 weeks). Controls were 20 early breast cancer patients who had been followed up with no prescription from biopsy until operation. Results: We could not find any statistically significant difference between the two groups regarding baseline clinical or tumor characteristics such as age, stage, grade, estrogen receptor, HER2 status or time, and type of surgery. However, the immunohistochemistry (IHS) study showed a decrease in median Ki67 from 35.14 to 29.6 in the intervention group (P-value= 0.02). While an increase from 24.5 to 30.6 was detected in the control group (P-value= 0.02). Both of these changes were statistically significant. Although mild gastrointestinal symptoms were seen in approximately 50% of cases, generally, patients tolerated metformin well. There was a correlation between the score of HOMA, a metabolic factor, and the changes in KI67. Conclusion: Metformin prescription in a short period of time between biopsy and definitive surgery leads to the inhibition of breast cancer cell growth. We found a relationship between metformin anti-proliferative effect and glucose and insulin metabolism.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"174 1","pages":"166-172"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metformin Efficacy on Proliferation Indices of Tumoral Cells in Non-Diabetic Patients with Invasive Breast Cancer Referring to the Cancer Institute of Iran\",\"authors\":\"S. Sadighi, M. Saberian, B. Behrouzi, M. Najafi, I. Jahanzad, R. Omranipour\",\"doi\":\"10.18502/BCCR.V11I4.5725\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Because of the decreasing effect of metformin on insulin resistance, it has been suggested as an anti-obesity and anti-cancer drug. So, we aimed to study the effect of metformin therapy on tumor cell proliferation in non-diabetic breast cancer patients. Methods: We conducted a prospective clinical trial and studied the effect of metformin therapy on the level of Ki67 as a measure of tumor cell proliferation. Our primary endpoint was to evaluate the changes in Ki67. The intervention group consisted of 25 non-diabetic breast cancer patients with no indication for neoadjuvant chemotherapy. They were followed up from the time of biopsy to operation. Metformin (1500 mg/day) was prescribed in the intervention group from the date of diagnosis until the surgery (2.8 weeks). Controls were 20 early breast cancer patients who had been followed up with no prescription from biopsy until operation. Results: We could not find any statistically significant difference between the two groups regarding baseline clinical or tumor characteristics such as age, stage, grade, estrogen receptor, HER2 status or time, and type of surgery. However, the immunohistochemistry (IHS) study showed a decrease in median Ki67 from 35.14 to 29.6 in the intervention group (P-value= 0.02). While an increase from 24.5 to 30.6 was detected in the control group (P-value= 0.02). Both of these changes were statistically significant. Although mild gastrointestinal symptoms were seen in approximately 50% of cases, generally, patients tolerated metformin well. There was a correlation between the score of HOMA, a metabolic factor, and the changes in KI67. Conclusion: Metformin prescription in a short period of time between biopsy and definitive surgery leads to the inhibition of breast cancer cell growth. We found a relationship between metformin anti-proliferative effect and glucose and insulin metabolism.\",\"PeriodicalId\":8706,\"journal\":{\"name\":\"Basic & Clinical Cancer Research\",\"volume\":\"174 1\",\"pages\":\"166-172\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic & Clinical Cancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/BCCR.V11I4.5725\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/BCCR.V11I4.5725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:由于二甲双胍降低胰岛素抵抗的作用,它已被建议作为一种抗肥胖和抗癌药物。因此,我们旨在研究二甲双胍治疗对非糖尿病乳腺癌患者肿瘤细胞增殖的影响。方法:我们进行了一项前瞻性临床试验,研究了二甲双胍治疗对Ki67水平的影响,Ki67水平是衡量肿瘤细胞增殖的指标。我们的主要终点是评估Ki67的变化。干预组由25例无新辅助化疗指征的非糖尿病乳腺癌患者组成。随访时间从活检到手术。干预组自诊断之日起至手术(2.8周),给予二甲双胍(1500mg /天)治疗。对照组是20名早期乳腺癌患者,他们从活检到手术都没有处方。结果:我们没有发现两组患者在基线临床或肿瘤特征(如年龄、分期、分级、雌激素受体、HER2状态或时间、手术类型)方面有统计学上的显著差异。然而,免疫组织化学(IHS)研究显示,干预组中位Ki67从35.14降至29.6 (p值= 0.02)。而对照组从24.5增加到30.6 (p值= 0.02)。这两种变化都具有统计学意义。虽然大约50%的病例出现轻微的胃肠道症状,但一般来说,患者对二甲双胍的耐受性良好。代谢因子HOMA评分与KI67的变化之间存在相关性。结论:在活检和最终手术之间的短时间内给予二甲双胍处方可抑制乳腺癌细胞的生长。我们发现二甲双胍的抗增殖作用与葡萄糖和胰岛素代谢有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Metformin Efficacy on Proliferation Indices of Tumoral Cells in Non-Diabetic Patients with Invasive Breast Cancer Referring to the Cancer Institute of Iran
Background: Because of the decreasing effect of metformin on insulin resistance, it has been suggested as an anti-obesity and anti-cancer drug. So, we aimed to study the effect of metformin therapy on tumor cell proliferation in non-diabetic breast cancer patients. Methods: We conducted a prospective clinical trial and studied the effect of metformin therapy on the level of Ki67 as a measure of tumor cell proliferation. Our primary endpoint was to evaluate the changes in Ki67. The intervention group consisted of 25 non-diabetic breast cancer patients with no indication for neoadjuvant chemotherapy. They were followed up from the time of biopsy to operation. Metformin (1500 mg/day) was prescribed in the intervention group from the date of diagnosis until the surgery (2.8 weeks). Controls were 20 early breast cancer patients who had been followed up with no prescription from biopsy until operation. Results: We could not find any statistically significant difference between the two groups regarding baseline clinical or tumor characteristics such as age, stage, grade, estrogen receptor, HER2 status or time, and type of surgery. However, the immunohistochemistry (IHS) study showed a decrease in median Ki67 from 35.14 to 29.6 in the intervention group (P-value= 0.02). While an increase from 24.5 to 30.6 was detected in the control group (P-value= 0.02). Both of these changes were statistically significant. Although mild gastrointestinal symptoms were seen in approximately 50% of cases, generally, patients tolerated metformin well. There was a correlation between the score of HOMA, a metabolic factor, and the changes in KI67. Conclusion: Metformin prescription in a short period of time between biopsy and definitive surgery leads to the inhibition of breast cancer cell growth. We found a relationship between metformin anti-proliferative effect and glucose and insulin metabolism.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信